ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.18Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $258,102,576.00
EPSttm : -1.22
Allogene Therapeutics, Inc.
$1.18
1.67%$0.02Float Short %
17.42
Margin Of Safety %
Put/Call OI Ratio
0.21
EPS Next Q Diff
0.04
EPS Last/This Y
0.32
EPS This/Next Y
0.01
Price
1.18
Target Price
8.15
Analyst Recom
1.36
Performance Q
-24.36
Relative Volume
1.68
Beta
0.32
Ticker: ALLO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | ALLO | 1.275 | 0.22 | 0.00 | 5224 |
| 2025-06-03 | ALLO | 1.356 | 0.20 | 0.38 | 5588 |
| 2025-06-04 | ALLO | 1.28 | 0.20 | 0.00 | 5608 |
| 2025-06-05 | ALLO | 1.3 | 0.20 | 0.00 | 5640 |
| 2025-06-06 | ALLO | 1.425 | 0.20 | 0.00 | 5616 |
| 2025-06-09 | ALLO | 1.41 | 0.10 | 0.20 | 10872 |
| 2025-06-10 | ALLO | 1.46 | 0.10 | 0.67 | 10918 |
| 2025-06-11 | ALLO | 1.45 | 0.10 | 0.01 | 10984 |
| 2025-06-12 | ALLO | 1.39 | 0.10 | 0.01 | 11055 |
| 2025-06-13 | ALLO | 1.33 | 0.10 | 0.19 | 11017 |
| 2025-06-16 | ALLO | 1.365 | 0.11 | 0.00 | 10989 |
| 2025-06-17 | ALLO | 1.3 | 0.11 | 0.00 | 10975 |
| 2025-06-18 | ALLO | 1.29 | 0.11 | 999.99 | 10943 |
| 2025-06-20 | ALLO | 1.225 | 0.11 | 0.61 | 10944 |
| 2025-06-23 | ALLO | 1.23 | 0.21 | 0.08 | 5639 |
| 2025-06-24 | ALLO | 1.25 | 0.21 | 0.03 | 5655 |
| 2025-06-25 | ALLO | 1.235 | 0.20 | 0.94 | 5773 |
| 2025-06-26 | ALLO | 1.19 | 0.21 | 0.10 | 5830 |
| 2025-06-27 | ALLO | 1.18 | 0.21 | 2.88 | 5900 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | ALLO | 1.27 | 17.9 | - | -1.01 |
| 2025-06-03 | ALLO | 1.35 | 17.9 | - | -1.01 |
| 2025-06-04 | ALLO | 1.28 | 17.9 | - | -1.01 |
| 2025-06-05 | ALLO | 1.29 | 17.9 | - | -1.01 |
| 2025-06-06 | ALLO | 1.42 | 17.9 | - | -1.00 |
| 2025-06-09 | ALLO | 1.41 | 18.6 | - | -1.00 |
| 2025-06-10 | ALLO | 1.47 | 18.6 | - | -1.00 |
| 2025-06-11 | ALLO | 1.46 | 18.6 | - | -1.00 |
| 2025-06-12 | ALLO | 1.40 | 18.6 | - | -1.00 |
| 2025-06-13 | ALLO | 1.34 | 18.6 | - | -1.00 |
| 2025-06-16 | ALLO | 1.37 | 18.6 | - | -1.00 |
| 2025-06-17 | ALLO | 1.29 | 18.6 | - | -1.00 |
| 2025-06-18 | ALLO | 1.29 | 18.6 | - | -1.00 |
| 2025-06-20 | ALLO | 1.23 | 18.6 | - | -1.00 |
| 2025-06-23 | ALLO | 1.23 | 18.6 | - | -1.00 |
| 2025-06-24 | ALLO | 1.25 | 18.6 | - | -1.00 |
| 2025-06-25 | ALLO | 1.23 | 18.6 | - | -1.00 |
| 2025-06-26 | ALLO | 1.20 | 18.6 | - | -1.00 |
| 2025-06-27 | ALLO | 1.18 | 18.6 | - | -1.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-03 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-04 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-05 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-06 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-09 | ALLO | -0.30 | 7.00 | 18.31 |
| 2025-06-10 | ALLO | -0.29 | 7.00 | 18.31 |
| 2025-06-11 | ALLO | -0.28 | 7.00 | 16.44 |
| 2025-06-12 | ALLO | -0.33 | 7.00 | 16.44 |
| 2025-06-13 | ALLO | -0.33 | 7.00 | 16.44 |
| 2025-06-16 | ALLO | -0.33 | 7.07 | 16.43 |
| 2025-06-17 | ALLO | -0.33 | 7.07 | 16.43 |
| 2025-06-18 | ALLO | -0.33 | 7.07 | 16.43 |
| 2025-06-20 | ALLO | -0.33 | 7.07 | 16.43 |
| 2025-06-23 | ALLO | -0.33 | 5.82 | 16.43 |
| 2025-06-24 | ALLO | -0.33 | 5.82 | 16.43 |
| 2025-06-25 | ALLO | -0.33 | 5.82 | 16.43 |
| 2025-06-26 | ALLO | -0.33 | 5.82 | 17.42 |
| 2025-06-27 | ALLO | -0.33 | 5.82 | 17.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.28
Avg. EPS Est. Current Quarter
-0.26
Avg. EPS Est. Next Quarter
-0.24
Insider Transactions
-0.33
Institutional Transactions
5.82
Beta
0.32
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
25
Sentiment Score
5
Actual DrawDown %
97.5
Max Drawdown 5-Year %
-97.9
Target Price
8.15
P/E
Forward P/E
PEG
P/S
P/B
0.67
P/Free Cash Flow
EPS
-1.23
Average EPS Est. Cur. Y
-1
EPS Next Y. (Est.)
-0.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.68
Return on Equity vs Sector %
-89.4
Return on Equity vs Industry %
-71.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.2
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading